Cogent Biosciences, Inc. Increase (Decrease) in Deferred Liabilities
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Deferred Liabilities of -$52.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2020-03-26
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2018-12-31 was -$17.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2018-09-30 was -$17.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2018-06-30 was -$14.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for the quarter ending 2018-03-31 was -$4.00K, a 150.00% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2018 was -$52.00K.
- Cogent Biosciences, Inc. increase (decrease) in deferred liabilities for fiscal 2017 was -$2.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$34.00K derived: sum of 2 quarters · filed 2020-03-26 | -$48.00K derived: sum of 3 quarters · filed 2020-03-26 | -$52.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$31.00K derived: sum of 2 quarters · filed 2019-11-12 | -$35.00K 10-Q · filed 2019-11-12 | -$40.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$18.00K 10-Q · filed 2019-08-12 | -$23.00K derived: sum of 3 quarters · filed 2019-08-12 | -$27.00K derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | -$4.00K 10-Q · filed 2019-05-13 | -$9.00K derived: sum of 2 quarters · filed 2019-05-13 | -$13.00K derived: sum of 3 quarters · filed 2019-05-13 | -$14.00K derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$9.00K derived: sum of 2 quarters · filed 2019-03-28 | -$10.00K derived: sum of 3 quarters · filed 2019-03-28 | -$2.00K 10-K · filed 2019-03-28 |
| 2017-09-30 | -$4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$5.00K derived: sum of 2 quarters · filed 2018-11-13 | $3.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $7.00K 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | $8.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |